Acute Ischemic Stroke
Conditions
Keywords
mechanical thrombectomy, stroke treatment, embolic protection, transcarotid
Brief summary
Study Objective is to establish the feasibility and safety of the NOVIS Transcarotid Neuroprotection System when used for the transcarotid intervention of patients that have a failed transfemoral endovascular therapy in the case of anterior circulation strokes due to large vessel embolic occlusions.
Detailed description
This is a prospective, multi-center, single arm feasibility study for the endovascular treatment of patients with acute ischemic anterior circulation strokes due to large vessel embolic occlusions using the transcarotid approach with flow reversal. Patients enrolled into the NITE 1 Study will have failed transfemoral therapy and will be followed immediately from post-op to 90 days.
Interventions
The NOVIS Transcarotid Neuroprotection System (NPS) is intended to provide transcarotid vascular access and embolic protection
Sponsors
Study design
Intervention model description
Patients with acute ischemic anterior circulation stroke due to large vessel embolic occlusion who are candidates for endovascular therapy and in whom transfemoral therapy failed.
Eligibility
Inclusion criteria
Summary: * 1\. Patients presenting with acute ischemic stroke of the anterior circulation with large vessel occlusions who are eligible for revascularization using endovascular therapies (stentrievers and/or aspiration devices) 2\. Occlusion of the intracranial ICA, MCA M1, proximal MCA M2, single-vessel MCA M2, dominant MCA M2, or co-dominant MCA M2 segments 3\. Patient has failed transfemoral therapy (see Appendix 4 for definition), and at least 15 minutes have elapsed from groin puncture
Exclusion criteria
Summary: * 1\. Significant disease of the ipsilateral common carotid artery on routine CTA 2\. Presence of a cervical ICA loop or other high-risk anatomical features of the ICA on routine CTA, that may preclude the use of the NOVIS NPS 3\. Any active or recent hemorrhage within the past 30 days 4\. Embolectomy contraindications a. Pre-stroke mRS ≥2 b. NIHSS ≤ 5 c. ASPECTS ≤ 5 5\. IV tPA has been or is being administered 6\. Last known well \> 24 hours ago
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Device-related Serious Adverse Events | 90 Days | The primary outcome measure assesses the number of vascular complications which include which include dissection, pseudoaneurysm, hematoma, arteriovenous fistula, thrombus formation, embolization and any vascular complication that may be attributed to the device AND requires surgical repair, surgical wound revision, transfusion, etc. The endpoint is measured at 90 days post-procedure. |
| Number of Other Serious Adverse Events | 90 Days | The primary outcome measure assesses the number of permanent cranial nerve injury, new symptomatic ipsilateral hemorrhage and dissections related to ancillary devices. The endpoint is measured at 90 days post-procedure. |
| Number of Subjects With Functional Independence | 90 Days | Functional independence will be evaluated by assessing the modified Rankin scale (mRS). The mRS comprises six levels from 0 to 5 of increasing severe disability with an additional level 6 indicating death. A lower score indicates a better outcome and a higher score indicates a worse outcome. A mRS score reported between 0 to 2 will be considered functionally independent and 3 to 6 to not be functionally independent or dead at point of measurement. The endpoint is measured at 90 days post-procedure. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Neurologic Assessment | 90 Days | The outcome measure measures neurological worsening of patients according to the National Institutes of Health Stroke Scale (NIHSS) at 90 days post procedure. The NIHSS is a graded neurological examination that assesses consciousness, eye movements, visual fields, motor and sensory impairments, ataxia, speech, cognition and inattention. The NIHSS is a combination of 11 components each with a particular scale as follows: level of consciousness (1a: 0-3, 1b: 0-2 and 1c: 0-2), best gaze (0-2), visual fields (0-3), facial palsy (0-3), arm motor (0-4), leg motor (0-4), limb ataxia (0-2), sensory (0-2), best language (0-3), dysarthria (0-2), extinction and inattention (0-2). The components are summed, and a lower score indicates better outcomes, and higher score indicates worse outcomes. A neurological worsening similar to a non-disabling stroke is considered scored less than or equal to 4 and a neurological worsening similar to a disabling stroke with a score equal to or greater than 5. |
| Carotid Access Time | Hospital arrival to neck incision, neck incision to carotid exposure, neck incision to carotid exposure, neck incision to carotid artery catheterization, neck incision to femoral venous sheath access which, and neck incision to initiation of reverse flow. | The endpoint measures the hospital arrival to neck incision, neck incision to carotid exposure, neck incision to carotid exposure, neck incision to carotid artery catheterization which includes the securement of the sheath, neck incision to femoral venous sheath access which includes the securement of the sheath, and neck incision to initiation of reverse flow. |
| Revascularization Sucess Rate | Start to end of index procedure | The outcome measure reports the number of patients with modified thrombolysis in cerebral infarction (mTICI) score evaluated by the contract core lab measuring angiograms collected from baseline to immediately after the end of the index procedure. The mTICI grading scale is a tool for determining the response of thrombolytic therapy for ischemic stroke on a scale between 0 to 3. A lower score indicates better outcomes and higher score indicates worse outcomes The score 2 has two additional grades of severity of 2a and 2b indicating worse outcomes along the alphabetical progression of the scale. |
| Technical Sucess Rate | Start to end of index procedure | The outcome measure will count the number patients with successful introduction of endovascular tools through the NOVIS Transcarotid NPS during the procedure. Introduction of endovascular tools will be considered successful if NPS was placed, reverse flow was established, and interventional tools were successfully delivered. |
| Time to Final Revascularization | Hospital arrival to OR, LKW to final revascularization, admission to final revascularization, OR to final revascularization, cutdown to final revascularization, arterial introduction of interventional tools to final revascularization, total reverse flow. | The endpoint measures the time of hospital arrival to operating room (OR), last known well to final revascularization, admission to final revascularization, OR to final revascularization, Cutdown to final revascularization, arterial introduction of interventional tools to final revascularization, total reverse flow time including common carotid artery (CCA) clamp to CCA unclamp. |
| Number of Device-Related Complications | 90 Days | This outcome measure assesses the number of reported complications that may be attributed to the device through the end of all patient follow up in the study. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| NOVIS Transcarotid Neuroprotection System (NPS) Patients that have failed transfemoral endovascular therapy in the case of anterior circulation strokes due to large vessel embolic occlusions will enrolled in the study and treated using the NOVIS Transcarotid NPS.
NOVIS Transcarotid Neuroprotection System (NPS): The NOVIS Transcarotid Neuroprotection System (NPS) is intended to provide transcarotid vascular access and embolic protection | 12 |
| Total | 12 |
Baseline characteristics
| Characteristic | NOVIS Transcarotid Neuroprotection System (NPS) |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 10 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 9 Participants |
| Region of Enrollment United States | 12 participants |
| Sex: Female, Male Female | 8 Participants |
| Sex: Female, Male Male | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 3 / 12 |
| other Total, other adverse events | 12 / 12 |
| serious Total, serious adverse events | 9 / 12 |
Outcome results
Number of Device-related Serious Adverse Events
The primary outcome measure assesses the number of vascular complications which include which include dissection, pseudoaneurysm, hematoma, arteriovenous fistula, thrombus formation, embolization and any vascular complication that may be attributed to the device AND requires surgical repair, surgical wound revision, transfusion, etc. The endpoint is measured at 90 days post-procedure.
Time frame: 90 Days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| NOVIS Transcarotid Neuroprotection System (NPS) | Number of Device-related Serious Adverse Events | 0 device-related serious adverse events |
Number of Other Serious Adverse Events
The primary outcome measure assesses the number of permanent cranial nerve injury, new symptomatic ipsilateral hemorrhage and dissections related to ancillary devices. The endpoint is measured at 90 days post-procedure.
Time frame: 90 Days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| NOVIS Transcarotid Neuroprotection System (NPS) | Number of Other Serious Adverse Events | 0 other serious adverse events |
Number of Subjects With Functional Independence
Functional independence will be evaluated by assessing the modified Rankin scale (mRS). The mRS comprises six levels from 0 to 5 of increasing severe disability with an additional level 6 indicating death. A lower score indicates a better outcome and a higher score indicates a worse outcome. A mRS score reported between 0 to 2 will be considered functionally independent and 3 to 6 to not be functionally independent or dead at point of measurement. The endpoint is measured at 90 days post-procedure.
Time frame: 90 Days
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| NOVIS Transcarotid Neuroprotection System (NPS) | Number of Subjects With Functional Independence | mRS of 0 to 2 | 4 Participants |
| NOVIS Transcarotid Neuroprotection System (NPS) | Number of Subjects With Functional Independence | mRS of 3 to 6 | 8 Participants |
Carotid Access Time
The endpoint measures the hospital arrival to neck incision, neck incision to carotid exposure, neck incision to carotid exposure, neck incision to carotid artery catheterization which includes the securement of the sheath, neck incision to femoral venous sheath access which includes the securement of the sheath, and neck incision to initiation of reverse flow.
Time frame: Hospital arrival to neck incision, neck incision to carotid exposure, neck incision to carotid exposure, neck incision to carotid artery catheterization, neck incision to femoral venous sheath access which, and neck incision to initiation of reverse flow.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| NOVIS Transcarotid Neuroprotection System (NPS) | Carotid Access Time | Hospital arrival to neck incision | 100.3 minutes | Standard Deviation 40.6 |
| NOVIS Transcarotid Neuroprotection System (NPS) | Carotid Access Time | Neck incision to carotid exposure | 13.5 minutes | Standard Deviation 5 |
| NOVIS Transcarotid Neuroprotection System (NPS) | Carotid Access Time | Neck incision to carotid catheterization (includes securement of sheath) | 20.4 minutes | Standard Deviation 7.5 |
| NOVIS Transcarotid Neuroprotection System (NPS) | Carotid Access Time | Neck incision to femoral venous sheath access (includes securement of sheath) | 6.8 minutes | Standard Deviation 11.9 |
| NOVIS Transcarotid Neuroprotection System (NPS) | Carotid Access Time | Neck incision to initiation of reverse flow | 35 minutes | Standard Deviation 13.2 |
Neurologic Assessment
The outcome measure measures neurological worsening of patients according to the National Institutes of Health Stroke Scale (NIHSS) at 90 days post procedure. The NIHSS is a graded neurological examination that assesses consciousness, eye movements, visual fields, motor and sensory impairments, ataxia, speech, cognition and inattention. The NIHSS is a combination of 11 components each with a particular scale as follows: level of consciousness (1a: 0-3, 1b: 0-2 and 1c: 0-2), best gaze (0-2), visual fields (0-3), facial palsy (0-3), arm motor (0-4), leg motor (0-4), limb ataxia (0-2), sensory (0-2), best language (0-3), dysarthria (0-2), extinction and inattention (0-2). The components are summed, and a lower score indicates better outcomes, and higher score indicates worse outcomes. A neurological worsening similar to a non-disabling stroke is considered scored less than or equal to 4 and a neurological worsening similar to a disabling stroke with a score equal to or greater than 5.
Time frame: 90 Days
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| NOVIS Transcarotid Neuroprotection System (NPS) | Neurologic Assessment | Non-Disabling Stroke (NIHSS ≤ 4) | 8 Participants |
| NOVIS Transcarotid Neuroprotection System (NPS) | Neurologic Assessment | Disabling Stroke (NIHSS ≥ 5 | 4 Participants |
Number of Device-Related Complications
This outcome measure assesses the number of reported complications that may be attributed to the device through the end of all patient follow up in the study.
Time frame: 90 Days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| NOVIS Transcarotid Neuroprotection System (NPS) | Number of Device-Related Complications | 1 complications |
Revascularization Sucess Rate
The outcome measure reports the number of patients with modified thrombolysis in cerebral infarction (mTICI) score evaluated by the contract core lab measuring angiograms collected from baseline to immediately after the end of the index procedure. The mTICI grading scale is a tool for determining the response of thrombolytic therapy for ischemic stroke on a scale between 0 to 3. A lower score indicates better outcomes and higher score indicates worse outcomes The score 2 has two additional grades of severity of 2a and 2b indicating worse outcomes along the alphabetical progression of the scale.
Time frame: Start to end of index procedure
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| NOVIS Transcarotid Neuroprotection System (NPS) | Revascularization Sucess Rate | mTICI score 2b | 10 Participants |
| NOVIS Transcarotid Neuroprotection System (NPS) | Revascularization Sucess Rate | mTICI score 3 | 2 Participants |
Technical Sucess Rate
The outcome measure will count the number patients with successful introduction of endovascular tools through the NOVIS Transcarotid NPS during the procedure. Introduction of endovascular tools will be considered successful if NPS was placed, reverse flow was established, and interventional tools were successfully delivered.
Time frame: Start to end of index procedure
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| NOVIS Transcarotid Neuroprotection System (NPS) | Technical Sucess Rate | Technical Sucess Achieved | 12 Participants |
| NOVIS Transcarotid Neuroprotection System (NPS) | Technical Sucess Rate | Technical Sucess Not Achieved | 0 Participants |
Time to Final Revascularization
The endpoint measures the time of hospital arrival to operating room (OR), last known well to final revascularization, admission to final revascularization, OR to final revascularization, Cutdown to final revascularization, arterial introduction of interventional tools to final revascularization, total reverse flow time including common carotid artery (CCA) clamp to CCA unclamp.
Time frame: Hospital arrival to OR, LKW to final revascularization, admission to final revascularization, OR to final revascularization, cutdown to final revascularization, arterial introduction of interventional tools to final revascularization, total reverse flow.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| NOVIS Transcarotid Neuroprotection System (NPS) | Time to Final Revascularization | Hospital arrival to operating room | 46.7 minutes | Standard Deviation 41.9 |
| NOVIS Transcarotid Neuroprotection System (NPS) | Time to Final Revascularization | Last known well to final reperfusion | 628.9 minutes | Standard Deviation 336 |
| NOVIS Transcarotid Neuroprotection System (NPS) | Time to Final Revascularization | Admission to final reperfusion | 156.7 minutes | Standard Deviation 32 |
| NOVIS Transcarotid Neuroprotection System (NPS) | Time to Final Revascularization | Operating room to final reperfusion | 110.0 minutes | Standard Deviation 43.05 |
| NOVIS Transcarotid Neuroprotection System (NPS) | Time to Final Revascularization | Cutdown to final reperfusion | 56.3 minutes | Standard Deviation 25.1 |
| NOVIS Transcarotid Neuroprotection System (NPS) | Time to Final Revascularization | Arterial introduction of interventional tools to final reperfusion | 22.0 minutes | Standard Deviation 24.2 |
| NOVIS Transcarotid Neuroprotection System (NPS) | Time to Final Revascularization | Total reverse flow time (CCA clamp to CCA unclamp) | 20.3 minutes | Standard Deviation 26.2 |